MedCAC Sets October Meeting To Debate AF Catheter Ablation Coverage
This article was originally published in The Gray Sheet
Executive Summary
The Medicare Evidence Development and Coverage Advisory Committee will meet Oct. 21 to see whether evidence shows that treating atrial fibrillation with radiofrequency catheter ablation is safe and effective
You may also be interested in...
MedCAC meeting
Medicare Evidence Development & Coverage Advisory Committee meeting Oct. 21 will review all methods of catheter ablation for the treatment of atrial fibrillation, not just radiofrequency energy-based systems, CMS clarifies Sept. 1 (1"The Gray Sheet" Aug. 24, 2009). Topics on the agenda include clinical comparisons, patient subpopulations, outcomes of interest, and appropriate physician training. MedCAC members will be asked to vote on their levels of confidence that ablation improves health outcomes for longer than one year
MedCAC meeting
Medicare Evidence Development & Coverage Advisory Committee meeting Oct. 21 will review all methods of catheter ablation for the treatment of atrial fibrillation, not just radiofrequency energy-based systems, CMS clarifies Sept. 1 (1"The Gray Sheet" Aug. 24, 2009). Topics on the agenda include clinical comparisons, patient subpopulations, outcomes of interest, and appropriate physician training. MedCAC members will be asked to vote on their levels of confidence that ablation improves health outcomes for longer than one year
DoJ Targets Five Cardiac Ablation Device Makers In False Claims Probe
Medtronic, Boston Scientific, St. Jude Medical and AtriCure are targeted in an ongoing Justice Department probe into alleged off-label promotion of cardiac ablation devices for atrial fibrillation